Republished with permission of Amy Tenderich of DiabetesMine.com
For at least three consecutive years now at the annual ADA Conference, we keep hearing about a rumored switchover from the A1c as the gold standard average glucose measurement. Instead, we'll get something new and supposedly easier to understand: a new measure that more closely reflects the mg/dL (and international mmol/l) numbers we all get on our home glucose meters. This new test is now dubbed the eAG (estimated average glucose).
One of the big news announcements Scientific Sessions this week was the results of a large international study that supposedly underscores the accuracy of the eAG. In this 10-center study, 507 volunteers with diabetes had their A1c translated into eAG readings and compared with their running daily BG results, if I understood the press materials correctly. "Study investigators found a simple linear relationship," the ADA press release states.
Also stated: "Patients find it difficult ...
To decide which health insurance plan is best for you, you need to determine how much you will be spending on medical care in the future. There are two ways to estimate your future costs: 1) Starting from scratch and estimating how much you will probably spend using average costs for the medical procedures you think you’ll need. 2) Looking at your Explanation of Benefits (EOBs) from last year to see what medical coverage you required, and guessing that the next year will be similar. If you’re starting from scratch, first list all the doctor visits, hospital visits (such as out-patient surgery), prescription drugs, laboratory tests, immunizations, x-rays, or other medical services you may seek in the next year. Then, multiply your expected number of visits, prescriptions, etc. by the average costs in the table below. (For quick explanations of terms like EOBs, co-pay, deductible, and co-insurance, check out our Health Insurance Glossary .) Doctor Visits (co-pay) - $30 per visit P...
The Food and Drug Administration surprised almost everyone on March 24 by approving the DexCom STS Continuous Glucose Monitoring System . Even DexCom’s President and CEO Andrew Rasdal seems to have been surprised.
He told analysts in a conference call on March 27 that he had expected an “approvable letter” requesting more information. I was surprised as anyone, even though a few months ago I bought stock in the company.
Even more surprising is that Rasdal says that they will start selling the STS system immediately and anywhere in the country. This is in marked contrast to the Medtronic Diabetes marketing strategy for the other continuous sensor, the Guardian RT. While it works out the reimbursement issue, Medtronic is limiting sales to just seven large cites .
Getting health insurance coverage is the big challenge for all continuous sensors simply because they are so expensive. Rasdal told analysts that those of us who can afford the out-of-pocket costs will be the company’s first ...
You should knowAnswers to your question are meant to provide general health information but should not replace medical advice you receive from a doctor. No answers should be viewed as a diagnosis or recommended treatment for a condition. Content posted by community members does not necessarily reflect the views of Remedy Health Media, which also reserves the right to remove material deemed inappropriate.